DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Therapeutics, the developer of TEPEZZA, prepared this document to address questions from the Thyroid Eye Disease (TED) community about the resumed production of TEPEZZA, a medicine for TED. Patients can now schedule their infusions. Read on for information about how to schedule infusions, insurance considerations and answers to other frequently asked questions.
Note: If you choose to share or post these FAQs, please share the full document and not select pieces of it, in order to comply with regulatory guidelines.
Questions about TEPEZZA? Talk to Horizon Patient Services.
Call 1-833-469-8331, Mon-Fri, 8 AM – 8 PM EST.
Horizon Patient Services does not provide individual patient care or medical advice.
News & MeetingsNew Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
News & MeetingsTeprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye DiseaseMost adults with thyroid eye disease rec...
News & MeetingsHorizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth DriversHorizon Therapeutics plc announced today...
News & MeetingsThe New England Journal of Medicine Publishes Comprehensive Data From Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (...Horizon Therapeutics plc announced that ...
News & MeetingsIntegrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effect...Horizon Therapeutics plc today announced...
News & MeetingsA Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseasePrior clinical trials of TEPEZZA(TM) hav...
News & MeetingsHorizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application...Horizon Therapeutics plc today announced...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.